REDUCING RISK

We’ll explore how COPA™ could support pain recovery post-surgical or for chronic use with the goal to reduce risk of addiction, and how it empowers both patients and care teams with secure, real-time medication control.

COUNTDOWN TO WEBINAR

-
Days
-
Hours
-
Minutes
-
Seconds
Learn More about Investing in Berkshire Biomedical

OUR STRATEGIC VISION FOR BERKSHIRE BIOMEDICAL

In this webinar, we will highlight:

  • Exploration of potential business paths including partnerships, licensing, institutional relationships, and IPO possibilities as milestones are achieved.
  • The broader strategic vision for the company's future growth and development.
  • If available, we’ll hear from a clinician, caregiver, or advisory voice to bring real-world perspective to the platform’s potential.

Meet the Host

John Timberlake has served as Berkshire Biomedical’s Chief Executive Officer, President, and a member of our Board of Directors since April 2021. Mr. Timberlake has more than 30 years of life sciences experience in bringing pharmaceuticals, medical devices, and drug-device combination products to market.

Featuring Berkshire's Senior Advisor

Tom King has served a Senior Advisor to the Company since 2018. Mr. King brings a wealth of knowledge from 40+ years of experience in biopharma leadership positions ranging from large to development-stage companies. Mr. King is currently the Executive Chair of Achieve Life Sciences, and on the Board of Directors of Kinaset Therapeutics, and Concentric Analgesics.

For investors, this session goes beyond the tech to show how and where COPA™ could improve or save lives.

Learn How to Invest in Berkshire Biomedical